期刊
NEURO-ONCOLOGY
卷 24, 期 11, 页码 1827-1844出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/neuonc/noac146
关键词
MEK inhibitor; neurofibroma; neurofibromatosis 1; plexiform; review
Plexiform neurofibromas are a common manifestation of neurofibromatosis type 1, with surgery being the main treatment option in the past. However, recent regulatory approvals of the MEK inhibitor selumetinib have provided new options for PN management. Currently, there is no consensus on the definition, diagnostic evaluation, surveillance strategy, and treatment indications for PN. This review provides consensus recommendations from NF1 experts to address these questions.
Plexiform Neurofibromas (PN) are a common manifestation of the genetic disorder neurofibromatosis type 1 (NF1). These benign nerve sheath tumors often cause significant morbidity, with treatment options limited historically to surgery. There have been tremendous advances over the past two decades in our understanding of PN, and the recent regulatory approvals of the MEK inhibitor selumetinib are reshaping the landscape for PN management. At present, there is no agreed upon PN definition, diagnostic evaluation, surveillance strategy, or clear indications for when to initiate treatment and selection of treatment modality. In this review, we address these questions via consensus recommendations from a panel of multidisciplinary NF1 experts.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据